Pharma’s Digital Pathology Build-Out; Part 1 – The State Of Play
Pharma companies are applying digital pathology throughout their research and development functions. Where are they now finding value?
You may also be interested in...
From biomarkers to treatment effect size, agency officials respond to some of more than a hundred questions that poured in during a webinar on development of drugs to treat the liver disease.
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.